Mice with a targeted deletion in TGF-b1 spontaneously develop CD4 þ T-cell-dependent multifocal inflammatory disease and autoimmune pathology. T cells from TGF-b1 À/À mice are strongly activated, but the mechanisms that lead to T-cell activation and organ pathology are not well understood. Recent work shows that TGF-b1 raises the threshold for signaling through the TCR, suppressing the response of T cells to mitogenic stimuli. This suggests the possibility that CD4 þ T cells in TGF-b1 À/À mice become aberrantly activated and cause damage in response to physiologic inputs that ordinarily are not sufficient for cell activation, such as homeostatic MHC-TCR interactions, cytokines, or adhesion molecules. This model predicts that pathology is largely antigen-independent, and that CD4 þ T cells, regardless of antigen specificity, will become activated in TGF-b1 À/À mice, with subsequent organ pathology. To test this model, we crossed BALB/c-TGF-b1 À/À mice with the DO11.10 TCR transgenic mouse. To obviate the possible development of nonclonotypic TCRs, we also bred in a deficiency in RAG-1. Cohorts of highly inbred BALB/c background TGF-b1 À/À mice with an increasingly restricted CD4 þ T-cell repertoire (TGF-b1 À/À mice; DO11.10-TGF-b1 À/À mice; DO11.10-RAG-1 À/À TGF-b1 À/À mice) were then analyzed for inflammatory organ pathology and T-cell activation. The data show that progressively restricting the CD4 þ T-cell repertoire improved survival, ameliorated target organ pathology, and reduced T-cell activation to control levels. Therefore, these results find no support for the involvement of atypical T-cell activation pathways in disease in TGF-b1 À/À mice. Rather, T-cell activation and pathology in TGF-b1 À/À mice appear to be functions of typical TCR activation pathways. This supports the hypothesis that immune pathology in TGF-b1 À/À mice is self-antigen triggered.
TGF-b1 is a critical regulator of tolerance and autoimmunity. Mice with a targeted deletion in TGFb1 spontaneously develop multifocal inflammatory disease and autoimmune pathology. The lungs and heart are affected in TGF-b1 À/À mice, with variable and strain-dependent involvement of other organs.
1,2 On the BALB/c background, hepatic pathology in the form of necroinflammatory liver disease is a particularly prominent feature. 3 Regardless of genetic background, TGF-b1 À/À mice succumb to progressive wasting and failure to thrive, typically dying before 3-4 weeks of age. The direct participation of the adaptive immune system is important, as these pathologies are absent in TGF-b1 À/À mice rendered B-and T-cell deficient, such as SCID-TGF-b1 mice. 5 The pathologic role of CD4 þ T cells has been unequivocally established, as specific depletion of the CD4 þ T-cell subset using a monoclonal antibody prevents disease development. 5 In addition, MHC Class II À/À TGF-b1 À/À double knockout mice (in which CD4 þ T cells are not generated because of a failure in positive selection) do not develop autoimmune or inflammatory disease. 6 TGF-b1 is an important inhibitor of CD4 þ T cells, inhibiting cell activation at several key mechanistic control points. [7] [8] [9] Importantly, TGF-b1 inhibits proximal TCR signaling 10 in part by inhibiting the Tec kinase ITK, Ca 2 þ flux, and the nuclear translocation of the NFAT transcription factor. 11 TGF-b1 raises the threshold for TCR signaling and the T-cell response to mitogenic stimuli. 12 As evidence for this, thymocytes from TGF-b1 À/À mice are hyperresponsive to TCR-mediated as well as TCR-independent mitogenic stimuli due to a lowered threshold for Ca 2 þ -dependent activation. 13 This suggests the possibility that CD4 þ
T cells in TGF-b1
À/À mice become aberrantly activated through triggers that ordinarily would not be sufficient to lead to activation. The survival of naïve T cells in the periphery is believed to require continual TCR signaling through recognition of self-MHC ligands, 14, 15 although this has been controversial. 16 Perhaps, in the complete absence of TGF-b1, a lowered TCR activation threshold permits self-MHC-TCR interactions to become sufficiently vigorous as to induce aberrant T-cell activation and autoimmune pathology. Another possibility is that non-MHC signals such as those delivered by cytokines 17, 18 or adhesion molecules (eg LFA-3/ CD2 19, 20 ) can, in a TGF-b1-deficient environment, activate T cells in vivo. We therefore considered the possibility that disease pathology in TGF-b1 À/À mice results from aberrant activation of CD4 þ T cells through pathways other than those delivered by specific cognate activating antigen. Nearly all CD4 þ
T cells from TGF-b1
À/À mice possess an activated/ memory phenotype, 3 consistent with this mode of Tcell activation. Furthermore, in analyses of TCR repertoire usage in BALB/c-TGF-b1 À/À mice, expansion of CD4 þ T cells occurs approximately equally in T cells from all TCR Vb expressing subsets (Richard T Robinson and James D Gorham, unpublished data).
We therefore sought to determine whether autoimmune pathology in TGF-b1 À/À mice requires the presence of a physiologic broad CD4 þ T-cell TCR repertoire, or, alternatively, whether pathology develops as long as there are CD4
þ T cells present, regardless of antigen specificity. This is particularly interesting with respect to the pathogenesis of autoimmune liver disease and the significant liver damage observed in BALB/c-TGF-b1 À/À mice, as the liver is subject to injury through 'bystander' pathways that appear not to depend on the presence of a liver-specific antigen. 21, 22 Thus, we crossed BALB/c-TGF-b1 À/À mice with the DO11.10 mouse, a BALB/c background TCR transgenic mouse with CD4 þ T-cell specificity for a peptide (OVA 323-339 ) from chicken ovalbumin. Nearly all T cells from this mouse express the transgenic TCR Va and Vb genes are CD4 þ , and recognize OVA presented by the class II MHC I-A d complex. The rearrangement of endogenous TCR Va gene segments is not completely suppressed in TCR transgenic mice, however, permitting the generation of T cells expressing a second nonclonotypic TCR Va chain and having dual antigen specificities. 23, 24 To obviate this possibility, we also bred in a RAG-1 deletion, rendering TCR transgenic DO11.10-TGF-b1 À/À mice incapable of generating additional TCR specificities. Thus, we generated cohorts of highly inbred BALB/c background TGF-b1 À/À mice with an increasingly restricted CD4
þ T-cell repertoire (TGF-b1 À/À mice; DO11.10-TGF-b1 À/À mice; DO11.10-RAG-1
À/À mice) and analyzed these for survival, target organ pathology, and T-cell activation.
Materials and methods

Mice
Mice were bred at the Dartmouth Medical School American Association for Accreditation of Laboratory Animal Care-accredited animal care facility and were treated humanely, according to National Institutes of Health guidelines. The derivation of inbred BALB/c-TGF-b1 þ /À mice has been described. 3, 25 Extensively back-crossed BALB/c-DO11.10 mice and BALB/c-RAG-1 À/À mice were obtained from the Jackson Laboratory and bred with BALB/c-TGF-b1 þ /À mice. Litters were screened by PCR of DNA from tail snips for TGFB1 and RAG1 genotypes as we have described 5 and for the DO11.10 TCRa transgene using the primers 5 0 -GAGCAGCTTCCTTCCATCCTGAGAG-3 0 and 5 0 -TGGCTCTACAGTGAGTTTGGTGCCA-3 0 .
Survival Curves
The day of birth was designated as day 0, and while some mice were found to have died without leading indications, most were euthanized when signs indicated suffering or the mice were moribund, including reduced movement throughout the cage, reduced feeding, and hunched posture. Statistical comparisons between survival curves are by the log-rank test, and were calculated using GraphPad Prism v. 4.
Isolation of Intrahepatic and Splenic Lymphocytes
TGF-b1 À/À or littermate control TGF-b1 þ /À mice were euthanized by overexposure to CO 2 . Livers and spleens were removed, weighed and homogenized in ice-cold serum-free RPMI 164 with a Powergen Tissue Homogenizer (Fisher) at its lowest speed. The homogenized liver was then washed with serum free RPMI and resuspended in 5 ml of 100 U/ml collagenase IV (Sigma Aldrich, St Louis, MO, USA) and 10 U/ml DNase I (Roche, Indianapolis, IN, USA) in serum-free RPMI. The organ/ digestion solution mixture was incubated at 371C for 45 min with inverting every 2 min. After washing with cold 2% FCS/RPMI, spleen or liver cells were resuspended in room temperature 2% FCS/RPMI and collected over a Ficoll (Sigma Histopaque 1.119) step-gradient. Cells were counted using Guava ViaCount and stained for flow cytometric analysis.
Serum Transaminase Analysis
Directly following euthanasia by overexposure to CO 2 , blood was collected into heparinized plasma 
TGF-b1
À/À mice here and RAG-1 À/À TGF-b1 À/À mice from that study are calculated to be not statistically significantly different (P ¼ 0.07). However, in the previous study, most RAG-1
À/À mice were euthanized prior to the onset of morbidity, so the conclusion that the survival of these two groups is not different must remain tentative.
Restricting the TCR Repertoire Ameliorates Organ Pathology in TGF-b1
À/À Mice A prominent feature of the TGF-b1 À/À phenotype on the BALB/c background is a significant degree of necroinflammatory liver disease, reflected in elevated circulating concentrations of the hepatocyte enzymes AST and ALT, indicative of the presence of hepatocellular damage. We have previously demonstrated that hepatic pathology is dependent on CD4 þ T cells. 5 To test whether DO11.10-TGF-b1 ' is used to indicate that data for RAG-1 þ / þ mice and for RAG-1 þ /À mice are combined. À/À mice from hepatocellular damage. Notably, AST and ALT were somewhat higher on average in DO11.10-TGF-b1 À/À mice than in littermate control DO11.10-TGF-b1 þ /À mice, and this was statistically significant for ALT (P ¼ 0.02), but not for AST. Inspection of the data shows that elevated AST and ALT were observed for some but not all DO11.10-TGF-b1
samples. Stratification of the data (Figure 2b) shows that AST and ALT increased with age, with statistically significant regression lines. Notably however, for the older DO11.10-TGF-b1 À/À mice, elevations in AST and ALT were much more moderate than those typically observed for TGFb1 À/À mice. In samples from DO11.10-TGF-b1 À/À mice on a RAG-1 À/À background, AST and ALT were lower than in TGF-b1 À/À samples ( Figure 2a ; Po0.0001 for both AST and ALT). AST and ALT were higher on average in DO11.10-RAG-1
þ /À mice, and this was statistically significant both for AST (P ¼ 0.006) and for ALT (P ¼ 0.0006). Stratification of the data (Figure 2c ) shows that AST and ALT did not increase with age for DO11.10-RAG-1 (Figure 2b ). For ALT, there was an apparent decrease with age, but the regression line was not statistically significant. Three DO11.10-RAG-1 À/À TGF-b1 À/À mice had very high ALT levels (4200 U/l; circled in Figure 2a and c). These same mice had no comparable elevation in AST (eg see Figure 2c ), and extensive histologic analyses of multiple liver sections from these three mice revealed fairly unremarkable histology, with no visible hepatocellular damage, and only occasional, mild portal inflammation (data not shown). Thus, for B10% of DO11.10-RAG-1 À/À TGF-b1
mice, ALT is strongly elevated, but this is apparently dissociated from other obvious signs of liver damage such as elevated AST or histologic abnormalities; the elevation in ALT for this subgroup of DO11.10-RAG-1 À/À TGF-b1 À/À mice remains unexplained at this point. Finally, and as we have previously reported (non-TCR transgenic), RAG-1 À/À TGF-b1 
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À/À mice exhibiting ALT 4200 U/l are circled.
CD4
þ T-cell receptor repertoire prevents immune pathology RT Robinson et al
We examined the pathology of organ damage histologically. Livers from littermate control TGFb1 þ /À mice, regardless of RAG-1 or DO11.10 status, were histologically normal (Figure 3a , and data not shown). The livers from TGF-b1 À/À mice showed a periportal infiltrate of mononuclear cells and neutrophils. Inflammation varied in intensity from one portal area to the next but all portal areas were affected. The composition of cells varied, with some portal areas having more neutrophils than others. Interface hepatitis was moderate. Periportal balloon degeneration was diffuse. All TGF-b1 À/À livers showed severe and extensive bridging necrosis. Livers from DO11.10-TGF-b1 À/À mice showed none of the widespread necrosis and extensive inflammation of TGF-b1 À/À livers. Inflammation was seen but varied from mouse to mouse. Some DO11.10-TGF-
b1
À/À livers showed no difference from wild type, while other DO11.10-TGF-b1 À/À livers showed mild portal inflammation (Figure 3a , arrow) with predominantly mononuclear cells and some neutrophils. Interface hepatitis was rare and mild, and was characterized by hepatocytes ringed by lympocytes. Livers from DO11.10-TGF-b1 À/À mice on a RAG-1
background exhibited no necrosis, and no detectable parenchymal or portal inflammation. In sections of lung, TGF-b1 À/À samples showed extensive perivascular (Figure 3b ) and peribronchiolar (not shown) inflammation. The histology of DO11.10-TGF-b1 À/À lungs was variable. When observed, inflammation in the lung consisted of rare collection of mononuclear cells around vessels, bronchioles (Figure 3b, arrow) , or, rarely, in the parenchyma. In DO11.10-RAG-1 À/À TGF-b1 À/À mice, (Figure 3c ) showed an infiltrate of mononuclear cells diffusely in the atria and ventricles. In the ventricles, this was predominantly subendocardial. In DO11.10-TGF-b1 À/À hearts, rare foci of mononuclear cells were present (Figure 3c, arrow) , except in one animal in which the heart showed a more extensive infiltrate of mononuclear cells. In DO11.10-RAG-1
À/À hearts, mononuclear inflammation was absent. Notably, in some DO11.10-RAG-1
À/À hearts, we observed a focal, predominantly neutrophilic, perivascular infiltrate around a large vessel by the atrium (not shown), which was not observed in littermate DO11.10-RAG-1 À/À heart (left ventricular wall) shows myocytes infiltrated by lymphocytes but not extensively (Figure 4f ). The myocytes appear viable with dark nuclei and striations.
To extend the histological analyses, liver, lung, and heart sections were analyzed in a blinded fashion and scored on a semiquantitative scale (0 ¼ no pathological changes; 3 ¼ severe pathological changes; see Materials and methods for details). Figure 5 shows the compiled data from a total of 5-7 TGF-b1 À/À mice per group. These results show that restricting the T-cell repertoire through introduction of the DO11.10 TCR transgenes largely but not completely reduced pathological changes in the liver, lung and heart of TGF-b1 À/À mice. Additional introduction of the RAG-1 deletion into DO11.10-TGF-b1 À/À mice further attenuated inflammatory pathological changes. We note that a few DO11.10-RAG-1 À/À TGF-b1 À/À mice demonstrated some pathological changes involving innate immune cells of the myeloid series, including the presence of alveolar macrophages in the lung, and neutrophilic perivas- 
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À/À mice uniformly show severe liver pathology as assessed either histologically or by plasma transaminase levels; by contrast, in DO11.10-TGF-b1 À/À mice, these measurements are lower, but do exhibit mouse-to-mouse variability. We explored this variability further. To determine whether the elevations in transaminases in DO11.10-TGF-b1 À/À mice reflected the degree of liver histopathology, we compared these two metrics of liver disease. The data show no obvious positive correlation between the degree of liver histopathology and either AST (Figure 6a ) or ALT (Figure 6b ). In addition, the degree of liver histopathology does not correlate with mouse age (Figure 6c) ; by contrast, plasma transaminase levels in DO11.10-TGF-b1 À/À mice do show a small positive correlation with age (see Figure 2b) . As observed for liver, the degree of histopathology in either lung (Figure 6d þ T cells were CD62L hi , indicating a low degree T-cell activation in these cell populations. A summary of data from three mice in each group (Figure 8g) indicates that introduction of the DO11.10 TCR transgenes reduces T-cell activation in TGF-b1 À/À mice, and that further introduction of the RAG-1 deletion eliminates T-cell activation. Inspection of the flow cytometry profiles from DO11.10-TGF-b1 À/À splenic CD4 þ T cells ( Figure  8d ) reveals that T-cell activation preferentially occurs in KJ1-26 À T cells, which presumably have antigen specificities other than OVA, and may be responsive to autoantigens.
We extended our analysis of CD62L expression to liver CD4 þ T cells. Forty two percent of control nontransgenic TGF-b1 þ /À liver T cells expressed high CD62L expression (Figure 9a ). Similar expression patterns were observed in hepatic DO11.10-TGF-b1
þ T cells, with 41.3% (Figure 9c ) and 43.6%, (Figure 9e ) respectively, expressing high CD62L. Examining the hepatic CD4
þ T-cell population in TGF-b1 À/À mice, we observed that, as in the spleen, most cells were CD62L lo (Figure 9b) . In DO11.10-TGF-b1 À/À samples, an intermediate frequency (22.0%) of hepatic T cells were CD62L hi (Figure 9d) , and in DO11.10-RAG-1
TGF-b1 À/À T cells, the expression of CD62L expression returned to control frequencies, at 41.8% (Figure 9f) . A summary of data from three mice in each group is shown (Figure 9g ). Among the KJ1-26 À population in the DO11.10-TGF-b1 þ /À mice, 
À/À mice displayed in Figures 2 and 5 are correlated. The analysis shows no obvious positive correlation between the extent of liver histopathology and levels of either (a) AST or (b) ALT. In addition, no correlation is seen between extent of histopathology in (c) liver (d) lung or (e) heart and the age of the mouse.
CD4
þ T-cell receptor repertoire prevents immune pathology RT Robinson et al CD62L hi expression was decreased (15.6%) compared with the KJ1-26 þ population (41.3%) (Figure  9c ), and CD62L expression was further reduced (6.9%) in the equivalent cell population in TGFb1 À/À mice (Figure 9d ). Taken together, these results show that progressive restriction of the TCR repertoire progressively prevents T-cell activation in TGF-b1 À/À mice.
Discussion
Mice with a targeted deletion of the gene encoding the regulatory molecule TGF-b1 develop an unrestrained Th1-mediated immune pathology 3, 5, 25 and die within weeks of birth.
1,2 On the BALB/c background, TGF-b1 À/À mice develop severe necroinflammatory liver disease and is a model for the human disease autoimmune hepatitis (AIH). 26 The presence of CD4 þ T cells is required for inflammatory disease and early death, but whether the immune response is antigen specific has not been established. Recently, it has been reported that TGFb1 significantly lowers the activation threshold for TCR triggering. 12, 13 Indeed, nearly all CD4 þ T cells isolated from TGF-b1 À/À mice express cell surface markers indicating cellular activation. 3 Moreover, expansion in the liver occurs in T cells representing all TCRVb chain subsets (Richard T Robinson and James D Gorham, unpublished data). Together, these data suggest the possibility that in the absence of TGF-b1, T cells become readily activated and induce pathology in vivo through cellular pathways that normally would not result in T-cell activation. Possibilities include self-MHC-TCR interactions and cytokine-receptor interactions that ordinarily act to maintain T-cell survival in the periphery, but do not activate T cells under normal physiologic conditions. 14, 15, 17 As the liver is susceptible to T-cell dependent 'bystander' injury (ie not mediated by liver-specific antigens), 21, 22 this hypothesis needed to be considered to further understand this mouse model of autoimmune hepatocellular damage. Our current study finds no support for such modes of T-cell activation and target organ injury in TGFb1 À/À mice.
To test the hypothesis that the presence of CD4 þ T cells is sufficient for the development of end organ damage independent of cognate antigen-TCR interaction, we bred TGF-b1 À/À mice with chicken ovalbumin-specific DO11.10 TCR transgenic mice. The presence of the DO11.10 TCR transgenes prolonged the survival of TGF-b1 À/À mice, ameliorated end-organ damage, and caused a reduction in the degree of cellular activation within the CD4 þ Tcell population. In addition, we bred to homozygozity a null allele for RAG-1 onto DO11.10-TGF-b1 À/À mice. This further improved survival, reduced endorgan damage, and completely eliminated aberrant cellular activation within the CD4 þ T-cell population. These data indicate that CD4 þ T-cell activation in TGF-b1 À/À mice does not occur 'non-specifically,' and that the mere presence of CD4 þ T cells is not sufficient for pathology. Rather the data support a model in which T-cell activation and the associated end-organ damage are driven by 'typical' TCRactivation signals, albeit in a pathologic autoimmune-prone environment (ie the absence of TGFb1). That CD4 þ T-cell numbers in spleens and livers were similar between DO11.10-TGF-b1
À/À and littermate control DO11.10-TGF-b1 þ /À mice and between DO11.10-RAG-1 À/À TGF-b1 À/À and littermate control DO11.10-RAG-1 À/À TGF-b1
þ /À mice indicates that the peripheral signals that maintain CD4 þ T-cell numbers are operative in TCR transgenic TGF-b1 À/À mice; however, these pathways are not sufficient to induce T-cell activation or T-cell dependent end-organ pathology.
Interestingly, in DO11.10-TGF-b1 À/À mice, a moderate degree of inflammation in liver, lung and heart was observed at the histological level. As RAG-1 is intact in these animals, and some rearrangement of the endogenous TCRa locus is therefore permitted, 
CD4
þ T-cell receptor repertoire prevents immune pathology RT Robinson et al it is likely that some CD4 þ T cells expressing endogenous TCRa genes are generated in DO11.10-TGF-b1 À/À mice. Indeed, we observed in both spleen and liver the presence of a significant population of CD4 þ T cells that did not stain with the clonotypic KJ1-26 monoclonal antibody, and therefore do not 
þ T-cell receptor repertoire prevents immune pathology RT Robinson et al express the transgenic TCRab combination. Rather, they presumably express a TCR complex likely composed of the transgenic TCRb subunit paired with an endogenous TCRa subunit, as previously described for DO11.10 mice. 24 In addition, KJ1-26 þ cells from these mice may express a second endogenous TCRa subunit, allowing the expression of two distinct TCR complexes (one clonotypic, the other nonclonotypic) on the same cell, as previously observed for wild-type T cells. 27, 28 Nonclonotypic TCRs should permit promiscuous antigen recognition by these cell populations, the expansion of self-reactive T cells, and the development of some inflammatory changes in the target organs. This inflammation appears to progress slowly, indicating either that the restricted TCR repertoire does not permit the generation of highly pathogenic T-cell clones, or that such clones are kept in check by the concomitant development of effective regulatory T cells. Our current studies do not permit us to distinguish between these two possibilities.
The human disease AIH is associated with the accumulation of CD4 þ T cells in the liver producing the Th1 cytokines IFN-g and TNF-a. 29, 30 While AIH is largely assumed to be an antigen-specific disease, the identification of liver specific antigens that may drive the T-cell aspect of the disease has been frustratingly elusive. Support for antigen specificity in the pathology of the immune response in AIH has relied heavily on the presence of high titer autoantibodies, such as antinuclear antibodies or antismooth muscle antibodies. 31 In some subtypes of AIH, specific autoantigens have been identified, such as cytochrome P450 2D6, 32 or formiminotransferase cyclodeaminase. 33 However, in the majority of AIH cases, autoantigens recognized by immunoglobulins have not been identified. Moreover, it is generally believed that pathology in AIH is primarily mediated by T cells, with autoantibodies playing only a minor role in pathogenesis. 34 Analysis of CDR3 usage in hepatic T cells from AIH patients indicates that the intrahepatic T-cell population is oligoclonal, not polyclonal. [35] [36] [37] This supports an antigen-specific model for the expansion of intrahepatic T cells in AIH, but the identities of the particular antigen(s) that may be involved remain unknown. In the current work, we find evidence in support of the hypothesis that T-cell activation and end-organ damage in TGF-b1 À/À mice are driven by specific antigen(s). These antigens are likely to be 'true' self-antigens, rather than those derived from intestinal flora, as TGF-b1 À/À mice raised under germ-free conditions nevertheless develop the characteristic autoimmune pathology. 38 This is in contrast to results from IL-2 À/À mice or TCRa À/À mice in which the development of autoimmune colitis is eliminated when mice are raised in germ-free conditions. 39, 40 Identifying the particular self-antigens driving autoimmune liver disease in BALB/c-TGF-b1 À/À mice should yield insight into the pathogenesis of autoimmune diseases of the liver and other organs. Human AIH has not been associated with a specific deficiency in TGF-b1 production. Indeed, available data support the converse. Serum TGF-b1 is elevated in AIH patients with active disease and returns to control levels at disease remission. 41 Similarly, TGF-b1 mRNA and protein expression is elevated in liver biopsies from AIH patients with active disease, but not in biopsies from patients in remission. 41 Interestingly, a recent study shows that AIH patients exhibit both an elevation of TGF-b1 serum levels as well as a deficiency in expression of a TGF-b1 receptor subunit in PBMC. 42 This suggests that the elevation in TGF-b1 cytokine expression may be accompanied by a reduced ability of immune cells to respond to TGF-b1, at least during active disease. Animal models show that T lymphocyte responsiveness to TGF-b1 is a critical factor in the development of immune mediated hepatocellular damage. Mice expressing a transgenic dominantnegative TGF-b1 receptor specifically in T cells are more susceptible than control mice to experimental AIH induced by injection of liver extracts. 43 No data exist on the expression of TGF-b1, its receptor, or the responsiveness of T cells or other immunocytes to TGF-b1 at the time of onset of AIH. We speculate that the elevated TGF-b1 seen in serum and liver during active AIH flares may represent compensatory overexpression of this immunosuppressive cytokine. Given the recognized role of TGF-b1, through its effects on liver stellate cells, in the development of fibrosis and cirrhosis, 44 understanding the relationship between TGF-b1 expression and cellular response, and the onset, progression, and remission of AIH, remains an important research objective.
